Myla Goldman - Concepedia

Author

Myla Goldman

Also Known As

Goldman,Myla D, Jacques Galipeau, M GOLDMAN, M Goldman, M. D Goldman, M. D. Goldman, M. Goldman, Myla D Goldman, Myla D. Goldman, Myla Goldman

149

Publications

5.9K

Citations

H-Index

105

Concepts

All Affiliations

University of Virginia Cleveland Clinic University of Illinois Urbana-Champaign Virginia Commonwealth University University of Alabama at Birmingham

About

Myla Goldman is an author at University of Virginia specializing in medicine, multiple sclerosis, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	27	2K
2	Health Sciences	14	16	823
3	Education	1	1	34
4	Engineering	1	1	12
5	Nursing	1	1	11

Myla Goldman

Publications

Citations

H-Index

Page 1

	Year	Citations
Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls Myla Goldman, Ruth Ann Marrie, Jeffrey A. Cohen Multiple Sclerosis Journal	2007	656
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension Raju Kapoor, Pei‐Ran Ho, Nolan Campbell, The Lancet Neurology Disease ProgressionNeurological DisorderImmunologyClinical TrialsNeurology	2018	327
Validity of performance scales for disability assessment in multiple sclerosis Ruth Ann Marrie, Myla Goldman Multiple Sclerosis Journal ReliabilityQuality Of LifeNeurological FunctioningPerformance AssessmentDisability	2007	281
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis Robert J. Fox, Christopher S. Coffey, Robin Conwit, New England Journal of Medicine	2018	270
Clinically meaningful performance benchmarks in MS Myla Goldman, Robert W. Motl, John Scagnelli, Neurology	2013	160
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis Myla Goldman, Robert W. Motl, Richard A. Rudick Therapeutic Advances in Neurological Disorders Disease ProgressionNeurological DisorderClinical NeurologyClinical TrialsMs Functional Composite	2010	143
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis Diego Cadavid, Jeffrey Cohen, Mark S. Freedman, Multiple Sclerosis Journal	2016	136
Pilot study of a ketogenic diet in relapsing-remitting MS J. Nicholas Brenton, Brenda Banwell, Anna Bergqvist, Neurology Neuroimmunology & Neuroinflammation	2019	128
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial John R. Corboy, Robert J. Fox, Ilya Kister, The Lancet Neurology Disease ProgressionNeurological DisorderMedicineNew Disease ActivityClinical Trials	2023	126
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS Robert J. Fox, Andrew Chan, Ralf Gold, Neurology Clinical Practice	2016	104

Page 1